

HEPATITIS C TREATMENT IN PEOPLE RECEIVING OPIOID SUBSTITUTION THERAPY

A DIFFICULT POPULATION?



Valente R¹, Sousa M¹, Nunes J¹, Gomes C¹, Gouveia C¹, Ferreira A¹
¹ Hospital Beatriz Angelo, Portugal
 monimsousa@gmail.com



6th International Symposium on Hepatitis Care in Substance Users • Jersey City/New York, USA • 6 - 8 September 2017

Introduction:

Hepatitis C Virus (HCV) infection treatment has changed significantly lately with all-oral direct acting antivirals (DAAs). Patients on opioid substitution therapy (OST) and substance users have been assumed as difficult to treat because of possible lack of adherence and potential side effects.

Objectives:

- support that current available DAAs can be used safely in this special populations
- compare adherence and sustained virological response (SVR)


Methods:

Clinical processes were reviewed of patients who completed HCV treatment from April 2015 until December 2016 in a District Hospital in Portugal. Assessment of demographics of patients receiving OST, characterization HCV infection, hepatic fibrosis, therapy and virological response.


Results:

203 patients completed Treatment DAAs (93% no previous treatment)


OST - 14,7% n - 30 (methadone or buprenorphine)




OST: 90% male, 97% former injecting drug use




OST: Most patients referred by primary care and drug addiction centers




OST: 20% had cirrhosis and 2 were treatment experienced
 60% had ongoing alcohol consumption, 50% were consuming other substances




OST: G1 most prevalent 67%



OST: Therapeutic choice Sofosbuvir + Ledipasvir (70%)



**OST: - irregularity on treatment adherence 10% (n- 3)
 - side effects 10% (n- 3) , but no need to stop treatment**



Conclusion:

Patients treated with DAAs receiving OST had *no lower treatment adherence, more adverse effects or lower SVR*. Therefore, we can conclude and support that these **patients can be treated safely, successfully and effectively** with the new all oral DAAs.

Bibliography:

1 - Dore, Gregory J., et al. "Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial." *Annals of Internal Medicine* 165.9 (2016): 625-634. 2 - Midgard, Håvard, et al. "Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study." *PloS one* 11.11 (2016): e0166451. 3 - Real-World Experience Treating Hepatitis C Virus (HCV) in Patients on Opioid Substitution Therapy in Rural Pennsylvania. Tuesdae Stainbrook DO MPH1; Sarjita Naik, PharmD2; 1Infectious Disease, DuBois Regional Medical Center, DuBois, Pennsylvania; 2Gilead Sciences, Foster City, California